
    
      Part A will access the pharmacokinetics of olaparib: Cohort 1 will investigate the single and
      multiple dose pharmacokinetics of olaparib following 300mg bd monotherapy dose(s); Cohort 2
      will investigate the single and multiple dose pharmacokinetics of olaparib following 100mg bd
      monotherapy dose(s) and the multiple dose pharmacokinetics in the presence of co-administered
      paclitaxel (80mg/m2 weekly on days 1, 8 and 15 of a single 28-day cycle).

      In Part B: Safety profile of olaparib 300mg bd as monotherapy and olaparib 100mg bd in
      combination with weekly paclitaxel will also be investigated in Chinese patients.
    
  